[Phase I-II study of recombinant interleukin-2]

Area of Science:

• Immunotherapy
• Oncology
• Pharmacology

Context:

• A phase I-II clinical trial investigated recombinant interleukin 2 (rIL-2) for treating lung and stomach cancers, including metastatic pulmonary tumors.
• The study aimed to evaluate the safety and efficacy of rIL-2, a biological response modifier (BRM).

Purpose:

• To assess the impact of different administration methods and dosages of rIL-2 on cancer treatment.
• To analyze the changes in lymphocyte cytotoxicity and subsets following rIL-2 administration.
• To examine the pharmacokinetics of rIL-2 in patients with thoracic and gastrointestinal malignancies.

Summary:

• Four distinct administration protocols for rIL-2 were employed, involving varying infusion durations, dosages, and schedules.
• Lymphocyte cytotoxicity against specific cancer cell lines (K562, PC-9, PC-14, Daudi) was measured pre- and post-treatment.
• Analysis included lymphocyte subset changes and rIL-2 pharmacokinetics to understand treatment response and potential challenges in BRM studies.

Impact:

• The study provides insights into the clinical application of rIL-2 in thoracic and gastrointestinal cancers.
• Findings contribute to understanding the immunological effects and pharmacokinetic profiles of rIL-2.
• The research addresses challenges in phase I studies of biological response modifiers, informing future therapeutic strategies.